We used these cell-based models to test a number of potential therapeutics for preeclampsia including (i) a well-established preventative treatment for preterm preeclampsia, aspirin (ACOG, 2019), (ii) a hypoglycaemic agent, metformin, emerging as a promising treatment of preeclampsia (Alqudah et al., 2018; Cluver et al., 2021; Decui et al., 2021), (iii) naturally occurring compound-derived drug, resveratrol (Shi et al., 2023), and (iv) a newly developed compound, AD-01, which is a based on an anti-angiogenic protein, FKBPL (McClements et al., 2013). This evidence concerns the gene PROS1 and preeclampsia.